To view this email as a web page, click here.

First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals

The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval.

Enasidenib: A Promising Option for IDH2-Mutated Acute Myeloid Leukemia?

The authors explored the evidence supporting the safety and side effect profile of enasidenib, FDA-approved in August 2017 for relapsed/refractory AML.

IN CASE YOU MISSED IT

Are Assessment Guidelines for HER2 Status Leading to Many False Positives?

Researchers tested whether the use of alternative control probes to classify HER2 status in breast cancer could lead to substantial false positives.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.